Ross, Amy Perrin
Besser, Christian
Naval, Shubhanvita
Stoneman, Dee
Gaunt, Harriet
Barker, Noreen
Article History
Received: 30 June 2022
Accepted: 31 January 2023
First Online: 27 February 2023
Declarations
:
: The survey was conducted in accordance with the market research guidelines as per European Pharmaceutical Marketing Research Association (EphMRA). According to the latest EphMRA guidelines, any market research does not require Clinical Research Ethics Committee or Independent Review Board approval. Therefore, no formal ethics committee and IRB approval was required [CitationRef removed]. All survey results were anonymized for the purpose of publication. In this report, the use of “patient” or “patients” refers to the feedback provided by the patient participants without attribution to any named individual. Participation was voluntary, and participants were entitled to withdraw at any stage of the process, or subsequently to ask that part or all of the record of their interview was destroyed or deleted. Adequate data protection was ensured, with data access strictly limited to the participants, Novartis, and the survey support team. All participants provided written informed consent to participate in the survey.
: Not applicable.
: Amy Perrin Ross has provided consultation to Biogen, Alexion, Genzyme, Genentech, Roche, EMD Serono, Novartis, Viela Bio, and Mallinckrodt. Noreen Barker participated in advisory boards and received support to attend educational meetings from Novartis in the past. Harriet Gaunt has no conflicts of interest. Christian Besser was an employee of Novartis during the analysis of this study until final version of paper development. Shubhanvita Naval and Dee Stoneman are employees of Novartis.